Suvretta Capital Management, LLC Terns Pharmaceuticals, Inc. Transaction History

Suvretta Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$4.86 - $8.19 $21.7 Million - $36.6 Million	-4,473,451 Reduced 76.64%	1,363,675 $8.95 Million
Q4 2023 Feb 14, 2024	SELL	$3.37 - $6.86 $690,122 - $1.4 Million	-204,784 Reduced 3.39%	5,837,126 $37.9 Million
Q3 2023 Nov 14, 2023	BUY	$4.7 - $8.55 $2.26 Million - $4.1 Million	480,075 Added 8.63%	6,041,910 $30.4 Million
Q2 2023 Aug 14, 2023	BUY	$7.35 - $13.29 $15.5 Million - $28.1 Million	2,113,560 Added 61.29%	5,561,835 $48.7 Million
Q4 2022 Feb 14, 2023	BUY	$4.62 - $10.18 $15.9 Million - $35.1 Million	3,448,275 New	3,448,275 $35.1 Million
Q4 2021 Feb 14, 2022	BUY	$5.65 - $10.73 $638,811 - $1.21 Million	113,064 Added 10.04%	1,238,800 $8.76 Million
Q3 2021 Nov 15, 2021	BUY	$7.22 - $13.46 $4,332 - $8,076	600 Added 0.05%	1,125,736 $11.7 Million
Q1 2021 May 17, 2021	BUY	$17.13 - $27.25 $19.3 Million - $30.7 Million	1,125,136 New	1,125,136 $24.8 Million

167

78.3M

580K

454K

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $216M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

Get notified when there are updates to the investment portfolio of Suvretta Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Suvretta Capital Management, LLC with notifications on news.